Merck 4Q Revenues: $16.4 billion +5% 4Q Earnings: $2.96 billion -21% FY Revenues: $65.0 billion +1% FY Earnings: $18.3 billion +7% Comments: Pharmaceutical sales were $14.8 billion, up 6%. The increase was primarily driven by growth in oncology as well as cardiometabolic and respiratory, partially offset by a decline in vaccines. KEYTRUDA sales were up 7% in the quarter to $8.3 billion. GARDASIL/GARDASIL 9 sales were down 34%, primarily due to lower demand in China. PROQUAD, M-...